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Abstract: Introduction: Demyelinating diseases of the central nervous system (CNS) comprise a 
group of neurological disorders characterized by progressive (and eventually irreversible) loss of 
oligodendrocytes and myelin sheaths in the white matter tracts. Some of myelin disorders include: 
Multiple sclerosis, Guillain-Barré syndrome, peripheral nerve polyneuropathy and others. To date, 
the etiology of these disorders is not well known and no effective treatments are currently available 
against them. Therefore, further research is needed to gain a better understand and treat these  
patients. To accomplish this goal, it is necessary to have appropriate animal models that closely 
resemble the pathophysiology and clinical signs of these diseases. Herein, we describe the model of 
toxic demyelination induced by cuprizone (CPZ), a copper chelator that reduces the cytochrome 
and monoamine oxidase activity into the brain, produces mitochondrial stress and triggers the local 
immune response. These biochemical and cellular responses ultimately result in selective loss of 
oligodendrocytes and microglia accumulation, which conveys to extensive areas of demyelination 
and gliosis in corpus callosum, superior cerebellar peduncles and cerebral cortex. Remarkably, 
some aspects of the histological pattern induced by CPZ are similar to those found in multiple  
sclerosis. CPZ exposure provokes behavioral changes, impairs motor skills and affects mood as that 
observed in several demyelinating diseases. Upon CPZ removal, the pathological and histological 
changes gradually revert. Therefore, some authors have postulated that the CPZ model allows to 
partially mimic the disease relapses observed in some demyelinating diseases. 
Conclusion: for five decades, the model of CPZ-induced demyelination is a good experimental 
approach to study demyelinating diseases that has maintained its validity, and is a suitable pharma-
cological model for reproducing some key features of demyelinating diseases, including multiple 
sclerosis. 
Keywords: Cuprizone, myelin, oligodendrocyte, demyelination, remyelination, white matter, neuroinflammation, multiple 
sclerosis, demyelinating disease, microglia. 
1. INTRODUCTION 
 Demyelinating diseases are neural disorders character-
ized by inflammation and damage or selective destruction of 
myelin associated with diffuse primary synaptic loss and 
progressive axonal degeneration [1-3]. Clinical deficits  
include ataxia, loss of dexterity, myoclony, spasticity,  
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paraparesis or hemiparesis, vision loss and cognitive deficits. 
These alterations are due to disrupted electrical transmission 
along axons because of myelin loss. A crucial characteristic 
of demyelinating diseases is the limited ability to rapidly 
regenerate myelin and the extension of secondary damage of 
axons. There are several causes of myelin destruction, in-
cluding immunological action, chemicals and infections [4]. 
Multiple sclerosis (MS) is associated with focal white matter 
plaques of demyelination, which are partially repaired during 
remyelination. Reappearance of oligodendrocytes within 
active lesions is frequently seen in patients at early stages of 
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MS. Some authors suggest that remyelination is a transient 
phenomenon and remyelinated shadow plaques may be af-
fected by new bouts of demyelination, which ultimately lead 
to incomplete myelin repair [5, 6]. There are several animal 
models that resemble the clinical and pathophysiologic 
course of MS. To date, four experimental approaches to in-
duce demyelination have been well-characterized and in-
clude: genetic myelin mutations, autoimmune inflammatory-
induced demyelination (experimental autoimmune encepha-
lomyelitis -EAE), virus-induced demyelination and toxic 
demyelination (cuprizone and lysolecithin models). All these 
models partially mimic the MS pathology. Although EAE is 
a commonly used model that reproduces some of the auto-
immune aspects of MS, the toxic demyelination with cupri-
zone can be still considered an appropriate model to study 
the remyelination process [7, 8]. 
 Cuprizone (CPZ) is a copper chelator that targets many 
metalloenzymes as ceruloplasmin, impairs the activity of the 
copper dependent cytochrome oxidase, decreases oxidative 
phosphorylation and produces degenerative changes in oli-
godendrocytes (OLs). This cascade of events eventually end 
in demyelination [9, 10]. In 2007, Zucconi, et al. found the 
copper deficiency induced by CPZ was related to microglial 
activation in cerebral cortex and thalamus [11]. This evi-
dence suggests that CPZ may reproduce different pathologi-
cal aspects of some neurodegenerative diseases [11]. The 
supplementation of animal diet with CPZ has been used as 
demyelinating model that mimics some histological hall-
marks of demyelinating diseases [12]. Cuprizone intoxica-
tion induces apoptosis of oligodendrocyte cell population 
that leads to extensive demyelination of white matter tracts 
in the corpus callosum, internal capsule, the thalamus, ante-
rior commissure and cerebellar peduncles [13, 14]. Interest-
ingly, when CPZ treatment is withdrawn, there is rapid re-
myelination and myelin proteins re-expression [15]. 
 The cuprizone-induced damage appears to be mediated 
by certain molecules, such as tumor necrosis factor alpha 
(TNFα), interleukin 1β (IL-1β) and interferon gamma 
(IFNγ) that are secreted by microglia/macrophages in the 
brain. These events are associated with a decrease in mito-
chondrial activity in OLs, low energy production, and high 
activity of reactive oxygen species [16]. The administration 
of CPZ in vivo leads to fast proliferation of micro-
glia/macrophages surrounding the lesion area. These im-
mune cells are known to produce TNFα, which seems to 
exacerbates acute demyelination and remains undetectable 
on untreated mice, as reported by Arnett et al. [17]. How-
ever, some important features of MS, such as inflamed blood 
vessels and the presence of CD3+ T cells, have not been de-
scribed in the CPZ model [18]. 
2. CUPRIZONE 
 CPZ, also referred as to cyclohexylidene hydrazide (Fig. 
1), is a condensation product of oxalylhydrazide and cyclo-
hexanone. CPZ is an effective and selective copper chelating 
agent. The first description of CPZ was made by Gustav 
Nilsson in the 1950s, he discovered that CPZ induced a sub-
tle blue color reaction upon chelating copper (Cu2+) salts 
[19]. In 1966, Carlton observed that CPZ administration in  
 
mice produced low serum Cu2+ levels and demyelination 
[20]. Later, it was found that oral administration of CPZ also 
produced severe status spongiosus, hydrocephalus and he-
patic lesions [21, 22]. 
3. COPPER METABOLISM 
 Copper is an essential element in all mammal’s nutrition. 
This element is a component of metalloenzymes in which it 
acts as an electron donor or acceptor [23]. Thus, copper is 
required for preserving tissue growth, cardiovascular integ-
rity, neuroendocrine function, neovascularization, lung elas-
ticity and iron metabolism. Cooper acts as a coenzyme in 
aerobic metabolism for cytochrome c oxidase in the mito-
chondria, lysyl-oxidase in the connective tissue, dopamine 
monooxygenase in the brain, and ceruloplasmin in the liver. 
Copper is also a cofactor for apo-copper-zinc superoxide 
dismutase (ApoCuZnSOD) that protects against oxygen-
free-radical damage to proteins, membrane lipids, and nu-
cleic acids in several systems. Severe copper deficiencies are 
relatively rare in humans and may occur by gene mutations 
or low dietary copper intake. Copper deficit may produce 
mental retardation, anemia, hypothermia, neutropenia, diar-
rhea, cardiac hypertrophy, bone fragility, immune deficien-
cies, connective tissue weakened, brain function impaired, 
peripheral neuropathy, and accelerate hair loss [24]. There-
fore, the copper metabolism is strongly regulated by a com-
plex homeostatic process [25]. 
 In mammals, absorption of copper primarily occurs in the 
small intestine. Copper absorption is performed by the brush 
border of the intestinal mucosa and transferred across the 
basolateral membrane into interstitial fluid and blood. Once 
copper is absorbed from the intestine, it binds to albumin and 
copper transport protein (transcuprein), and reaches serum 
levels of 40 mg Cu/L, approximately. Most of the serum 
copper is then deposited into the liver (Fig. 2). Nonetheless, 
only ≈I80 µg Cu2+ remains associated with albumin in hu-
man plasma. The rest of the copper (≈1000 µg per liter 
plasma) is bound to ceruloplasmin (65%, approximately), 
transcuprein (12%), and other components of low molecular 
weight. Most of the incoming copper rapidly finds its way 
into the hepatic cells (Fig. 2), and minimal amounts of this 
metal enter the kidney. There are two phases of copper dis-
tribution into the blood serum. The first phase is mediated by 
transcuprein that facilitates copper intake into the liver. The 
second phase is mediated by ceruloplasmin that helps in-
crease the copper levels into systemic organs (Fig. 2). The 
main role of copper is to function as a cofactor for specific 
enzymes and electron transport proteins involved in ener-
getic or anti-oxidative metabolism [26]. 
 
Fig. (1). Molecular structure of N,N’-bis(cyclohexylideneamino) 
oxamide (cuprizone). Molecular formula: C14H22N4O2; molecular 
weight: 278.45008g/mol. 
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4. CUPRIZONE AS DEMYELINATION MODEL 
 Since 1960s, several studies have been designed to de-
termine the precise dose of CPZ to produce significant 
changes in the CNS. Significant myelin changes have been 
observed when 0.2% - 0.6% CPZ is mixed with standard 
rodent chow [22]. The most common protocol consists in 
feeding 8-week-old mice with 0.2 % CPZ (w ⁄ w) for 5-6 
weeks (Fig. 3). Lindner et al. in 2008 demonstrated that high 
levels of demyelination can be achieved by increasing the 
dosage to 0.3% CPZ (w ⁄ w) [27]. However, as the CPZ con-
centration increases (from 0.2 % to 0.3%) the mortality rate 
rises from < 5 % to more than 10 % or 15 % [28]. Thus, the 
0.2% CPZ is the preferred concentration because it produces 
extensive demyelination with less side effects [29-34]. 
 Oligodendrocyte apoptosis begins a few days after cupri-
zone administration. Recently, Hesse and colleagues demon-
strated that oligodendroglial cell death and myelin gene 
downregulation start a few days after CPZ supplementation, 
but demyelination is only evident a few weeks after [35]. 
Recent evidence has shown that short-term exposure to CPZ 
(3 weeks) is enough to induce demyelination [29]. Astroglio-
sis and depletion of mature OLs is observed at 5th week. 
Similar histological changes can be observed with CPZ ex-
posure for five weeks. Hence, it seems that once the mature 
OLs are perturbed the demyelinating activity progresses 
without needing additional exposure. Interestingly, early 
withdrawal of CPZ did not accelerate the recovery process, 
which suggests that a mild white matter insult triggers a cas-
cade of demyelinating events in the following weeks [36]. 
Although matter degeneration in the CC is a key neuro-
anatomical sign of the CPZ model [33, 37, 38], several brain 
regions are also affected by CPZ (Table 1) [14, 32, 33, 37, 
39-52]. The histopathological changes produced by CPZ 
include oligodendroglial cell death, microglia activation, 
astrocyte reactivity and grey matter demyelination [53]. 
 Recent studies have demonstrated that juvenile mice are 
more vulnerable to CPZ. In fact, aged mice require high 
 
Fig. (2). Copper absorption and distribution. Copper values indicate the average of daily amounts of copper ingested, absorbed, secreted 
or excreted through different tissues. Modified from Linder & Hazeg-Azam [105]. 
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Fig. (3). Cuprizone effects in the CD1 mouse brain. CD1 mice received 0.2% CPZ for 6 weeks. 30-µm-thick coronal sections immu-
nostained with anti-myelin basic protein (MBP) and revealed with 3,3'-Diaminobenzidine. The control animal (A) shows a strong expression 
of MBP in the corpus callosum (CC), whereas the cuprizone-treated mouse (B) expresses low levels of MBP. CTX: cortex. Bar = 5µm. 
 
Table 1. Cuprizone demyelination over susceptible regions. 
Brain Region 
CPZ  
Concentration 
Initial 
Demyelination (Week) 
Complete  
Demyelination (Week) 
Microgliosis 
Initiation (Week) 
Astrogliosis  
Initiation (Week) Refs. 
Corpus callosum 0.1% – 0.5% 3 4.5 1 3 [32, 33, 39] 
Anterior commissure 0.2%, 0.25% 5 N/R 5 N/R [40-42] 
Basal ganglia (caudopu-
tamen, globus pallidus) 
0.2% – 0.4% 2 5 5 2 [40-44] 
Brainstem 0.2% N/R 5 N/R N/R [41, 106] 
Cerebellum 0.2%, 0.5% 2 5 2-3 3-4 
[20, 47, 48,  
106-108] 
Cortex 0.2% – 0.5% 4 5 3 3 
[39-41, 49,  
109-111] 
External Capsule 0.2% N/R 6 N/R N/R [110] 
Fornix 0.2%, 0.25% 5 12 5 N/R [40, 111] 
Hippocampus 0.2% – 0.4% 3 5 N/R 5 [41, 51, 109-112] 
Hypotalamus 0.2% 6 N/R N/R N/R [110] 
Internal capsule 0.25% 5 N/R 5 5 [40] 
Olfactory bulb-tract 0.2%, 0.25% 5 5 5 N/R [40, 41, 110, 111] 
Optic chiasm 0.2% N/R 5 N/R N/R [41] 
Optic tract 0.25% 5 N/R 5 N/R [40] 
Septal nucleus 0.25% 5 N/R 5 N/R [40] 
Substantia innominata 0.25% N/R 5 5 N/R [40] 
Thalamus 0.2%, 0.25% 6 5-6 5 5 [40, 110] 
Several brain regions have been reported to be susceptible to CPZ induced demyelination and show microgliosis and astrogliosis. N/R, Not reported. 
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doses of CPZ to achieve a similar degree of demyelination as 
compared to young mice, but the precise mechanism under-
lying this effect is still unknown. CPZ-induced demyelina-
tion in the corpus callosum of juvenile mice is more severe 
than that of middle-aged animals. Young mice (<57 days) 
exposed to CPZ show working memory deficit throughout 
both the CPZ intoxication period and the remyelination 
process (CPZ removal). In contrast, old mice (>57 days) 
only show working memory deficit immediately after CPZ 
exposure [54]. This age-related vulnerability also results in 
profound behavioral dysfunctions in young-adult mice, in-
cluding anxiety, attention deficit hyperactivity disorder and 
schizophrenia-like phenotypes. [55, 56]. At week four after 
CPZ exposure, motor deficits are also observed as observed 
in the rotoroad test and the open field maze [57-59]. The 
proclivity of young mice to demyelination may be explained 
by age-related changes in the expression of PDGFRα, Nkx-
2.2 and Olig2 [60] that, in turn, modify the recruitment of 
oligodendrocyte progenitor cells and drive the cell fate of 
neural progenitors toward the astrocyte lineage [61-64]. In-
terestingly, short-term exposure to cuprizone do not produce 
evident demyelination, but induces astrocyte and microglia 
activation that have been associated with work memory im-
pairment and social behavior disruption [65, 66]. Further 
evidence indicates some sex-related differences in CPZ-
induced demyelination. In this regard, Ludwin reported that 
Swiss and SJL/J female mice did not show demyelination as 
compared to males. However, no significant intersex differ-
ences were observed in C57BL/6 mouse strain [67, 68]. 
C57BL/6 is the mouse strain most commonly used for the 
CPZ demyelination model [33, 69]; however, many other 
mouse strains and animals species have been used to study 
different aspects of the demyelinating effect of CPZ (Table 2). 
 Recently, a modification in the CPZ model was described 
and consisted in the addition of 10 mg/kg i.p. rapamycin five 
times per week. This mTOR inhibitor produces extensive 
demyelination and prolongs the remyelination period, which 
help evaluate the effect of remyelinating treatments and 
downstream mechanisms involved in remyelination [70, 71]. 
Besides the CPZ model, other demyelinating models have 
been designed to reproduce the pathological course of de-
myelination and investigate possible treatments against MS 
(Table 3). Patients with MS may display three different 
clinical presentations: the relapsing-remitting form (RRMS) 
that is characterized by exacerbations of the symptoms (re-
lapses), followed by periods of complete or partial remis-
sion; the primary progressive form (PPMS) that shows a 
continuous and irreversible evolution of the disease; and the 
secondary progressive form (SPMS) in which there is a pro-
gressive worsening of neurologic function over time, proba-
bly as a transition from RRMS [72]. To date, there are sev-
eral experimental models that mimic some of the MS fea-
tures and all of them have different characteristics. The auto-
immune or allergic experimental encephalomyelitis (EAE) 
model in SJL/J mice is useful to study the relapsing forms. 
The MOG35-55 immunization of C57BL/6 mice is a good 
model to study a chronic-progressive disease [73] and it 
properly resembles the physiopathology of MS patter-II le-
sions [74]. The Theiler’s murine encephalomyelitis virus 
(TMEV) model, in which mice develop a chronic progres-
sive demyelinating disease without remissions [75] and their 
histopathological patterns look alike the patterns III and IV 
of MS lesions [76]. The lysolecithin injection model that 
produces focal and delimitated demyelinating lesion with 
microglia/macrophage activation and recruitment, which 
provides a fast and well-defined remyelination pattern com-
parable to the patter III of MS lesions [38, 77, 78]. Finally, 
the CPZ model can be considered as a suitable model to re-
produce extensive pattern-III lesions of MS [79], which are 
characterized by the presence of apoptotic OLs and early 
down regulation of myelin-associated glycoproteins (MAG) 
[80, 81]. The CPZ model also allows to the study of mecha-
nism of spontaneous remyelination, because the mechanism 
of demyelination/remyelination occurs simultaneously and 
the white-matter damage reverts after CPZ withdrawal re-
sembling the RRMS [82]. In summary, the choice of the best 
model depend on the aim of study and the characteristics of 
the treatment to be evaluated (Table 3). 
5. MECHANISM OF ACTION OF CPZ-INDUCED 
DEMYELINATION 
5.1. Mitochondrial Response to CPZ Intoxication 
 The oral administration of CPZ via daily diet in adult 
mice produces a specific insult to mature oligodendrocytes 
by impairing their metabolic demands to support myelin 
production and by triggering oligodendroglia apoptosis [83]. 
These events are followed by microglia recruitment and 
myelin phagocytosis. Morphological and gene-expression 
studies indicate that during the CPZ administration some 
oligodendrocyte progenitor cells keep proliferating and in-
vading demyelinated areas, but the magnitude of CPZ effect 
always ends in severe copper deficiency and secondary de-
myelination [14, 84-86]. Remarkably, demyelination and 
Table 2. CPZ susceptibility of diverse mouse/rat strains and 
other animal species. 
Mice Strain/ Species Demyelination Severity Refs. 
C57BL/6 mice Male ++ / Female ++ [32-33, 39, 43] 
ICI Mice Male ++ [14] 
Swiss-Webster Mice Male ++ [113] 
Swiss Mice Male ++ / Female - [61] 
Albino Mice Male ++ / Female ++ [114] 
SJL Mice Male ++ / Female + [69] 
129/SVJ Mice Male ++ [43] 
BALB/cJ Mice Male + [49] 
CD1 Mice Male ++ [115] 
Cynomolgus Macaque Male - / Female - [116] 
Wistar rat Male ++ / Female++ [117-120] 
Guinea Pig Male ++ [119] 
The CPZ demyelination pattern depends on the concentration, exposure time, sex, 
strain, and specie. (++) Acute; (+) Mild; (-) Not found. 
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oligodendrocyte damage produced by CPZ is not associated 
with injury of other neural cell types [85]. These findings 
contrast with those observed in liver, where the formation of 
megamitochondria (mitochondria enlargements or clusters) 
has been observed in hepatocytes. This alteration in liver 
mitochondria may be a consequence of deficient activity of 
cytochrome oxidase [16, 61, 85, 87, 88]. Interestingly, CPZ 
leads to a reduction in brain activity of cytochrome oxidase, 
monoamine oxidase (MAO) and inhibition of complexes I, 
II and III of the respiratory chain. After the CPZ intoxica-
tion, the formation of megamitochondria has been observed 
in liver, but not in neurons, astrocytes and other neural cells 
[16, 87, 89]. Remarkably, studies have confirmed that CPZ 
only affects mature oligodendrocytes, without modifying the 
absolute number of oligodendrocyte progenitor cells (OPCs) 
[85]. Consequently, CPZ does not affect de novo formation 
of oligodendrocytes. 
 Oxygen free radicals appear to be responsible for mito-
chondria enlargement. This process may be a protective reac-
tion to reduce and suppress intracellular reactive oxygen 
species (ROS) levels, which restore normal cellular func-
tions and organelle structure. However, if ROS levels dra-
matically increase into the oligodendrocytes and the resting 
membrane potential decreases with a concomitant caspase-3 
activation and demyelination. During the first 3 weeks of 
CPZ intoxication the caspase-3 is strongly active. Next, the 
caspase-3 activity decreases, whereas the activity of poly 
ADP-ribose polymerase (PARP) increases and induces 
apoptosis via the apoptosis inducing factor (AFI) [29, 90, 
91]. Hence, this evidence indicates that CPZ intoxication 
increases oxidative stress that, in turn, triggers apoptosis in 
mature OLs (Fig. 5) [83]. 
5.2. Lipid Metabolism Disturbance 
 Besides the inhibition of myelin protein synthesis, myelin 
lipid metabolism is also affected by cuprizone. Myelin sheet 
consist of 70% lipids, 40% phospholipids (mainly plasmalo-
gens), and 30% proteins [92]. Membrane-bound plasmalo-
gens can be hydrolyzed by plasmalogenase, leading to an 
increase of free plasmalogens. Phospholipase A2 (PLA2) 
can degrade both membrane-bound and free plasmalogens 
into arachidonic acid (AA), a key intermediate of pro-
inflammatory signaling. The activity of both plasmalogenase 
and PLA2 is increased by CPZ intoxication, which contrib-
utes to myelin sheath degradation and elevated concentra-
tions of AA [83]. In MS lesions, the AA cascade is activated 
by increasing activity of PLA2 and cyclooxygenase 1 or 2 
(COX-1, COX-2). The produced AAs will be subsequently 
metabolized by COX-1 or COX-2 into prostaglandin H2 
(PGH2) that strongly increase prostaglandin E2 (PGE2) 
related to OLs apoptosis via PGE2-E2 receptor, prostacyclin 
(PGI2), prostaglandin D2 (PGD2) and prostaglandin F2α 
(PGF2 α). Interestingly, this AA cascade is activated by 
cuprizone and is associated with a substantial involvement of 
sPLA2 isoform [93]. 
 Other organic compounds involved in the myelin sheet 
formation are cerebrosides (glycosphingolipids) and choles-
terol [92]. These lipidic compounds are drastically reduced 
by increased activity of plasmogenase during early stages of 
CPZ intoxication, and these findings are comparable to the 
increased phospholipase (PL) A1 and A2 activity found in 
MS and other neurodegenerative diseases [94-96]. These 
events produce myelin vacuolation and fluid accumulation 
between myelin lamellae with extensive space-occupying 
lesions, which cause axoplasmic displacement and axonal 
Table 3. Comparison of the most commonly used demyelination models. 
Model Specie Chemical Agent Demyelination 
Administration 
Route 
Spontaneous 
Remyelination 
Complexity Disadvantages Refs. 
Cuprizone 
Rat, 
Mouse 
Cuprizone 
Initial: 3 weeks 
Complete: 4.5 
weeks 
Oral 
Yes (completed 
at week 4) 
Low [mixed 
with chow 
Not validated for 
functional readouts 
in some strains 
[32, 39, 
86] 
Lysolecithin 
Rat, 
Mouse 
Lysophosphatidylcholine 
Initial: 2 days 
Complete: 1 week  
 Intracerebral 
injection 
Yes (completed 
at week 4) 
 High 
[Stereotactic 
surgery] 
High technical 
complexity 
[121-
123] 
EAE* 
Rat, 
Mouse, 
Guinea 
pigs 
CFA+MOG/MBP/PLP 
peptides or rSCH 
Initial: 11 days 
Complete: 2 
weeks 
Intraperitoneally  No 
Low [i.p. 
inyection] 
More related to 
ADEM than MS. 
Not for investigat-
ing remyelination 
process 
[124-
125] 
TMEV Mouse 
Theilovirus (cardiovi-
rus/piconaviridae). TO and 
GDVII subtypes 
Initial: 6 weeks 
Complete: 35 
weeks 
Oral, intranasal, 
footpad inocula-
tion, intracerebral 
injection 
No 
High [Stereo-
tactic sur-
gery, virus 
culture] 
The proportion of 
the disease caused 
by the virus activity 
or the inflammatory 
response is hard to 
determine 
[8, 126-
127] 
EAE: experimental autoimmune encephalomyelitis; TMEV: Theiler’s murine encephalomyelitis virus; CFA: complete Freund adjuvant; rSCH: rat spinal cord homogenate; MOG: 
myelin oligodendrocyte glycoprotein; MBP: myelin basic protein; PLP: proteolipid protein; W: weeks; ADEM: acute disseminated encephalomyelitis. * Demyelination pattern 
reported in the EAE model study was carried out on optic nerve of SJL/J mice, but demyelination pattern may variate between specie, strain and brain region. 
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Fig. (4). Time course of demyelination induced by 0.2% cuprizone feeding. Oligodendrocyte death begins at day three to seven and this 
event is followed by myelin protein degradation that approximately occurs at week one to three (early demyelination). At 4th week, the severe 
demyelination period begins and culminates at 5th - 6th weeks, when a complete demyelination is observed in many brain regions. The recov-
ery process (remyelination phase) is detectable in the first week after cuprizone withdrawal, but it is more significant between the weeks two 
and four. 
 
Fig. (5). Mitochondrial response to CPZ and lipid metabolism disturbance. Cuprizone induces alterations in many Cu dependent en-
zymes, generate increased oxidative stress leading to apoptosis and impairing the synthesis of key compounds in the myelin formation. (∆ψm, 
mitochondrial membrane potential). 
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disruption [14, 97]. Although myelin vacuolation is reversi-
ble, demyelination becomes irreversible by cell-body degen-
eration of mature oligodendrocyte [67]. OLs degeneration 
and apoptosis precede the CPZ-induced demyelination. This 
sequence of events suggests that the initial deterioration of 
OLs is not linked to autoimmune response against myelin 
proteins. A few days after CPZ treatment, oxidative stress 
induces degeneration of oligodendrocyte and myelin sheath 
that progresses to OLs apoptosis. Once mature OLs are dis-
rupted, a sequence of cellular and inflammatory processes 
drive caspase-3-triggered apoptosis and demyelination [36]. 
Caspase-3 is a crucial apoptotic protease [98] that is ex-
pressed at initial stages of cuprizone model in most of the 
injured oligodendrocytes. At later stages, the percentage of 
caspase-3-expressing oligodendrocytes decreases gradually 
until it is completely absent at 3th week. This evidence sug-
gests a biological switch in the cell-death mechanism trig-
gered by CPZ, that begins with a caspase 3-dependent 
mechanism and progressively changes to a caspase 3-
independent cell death [29] (Fig. 5). 
5.3. Immune System Influence in the CPZ Model 
 The classical hypothesis indicated that cuprizone intoxi-
cation produced a direct cell-autonomous toxicity in mature 
OLs with the concomitant demyelination. However, inflam-
matory mediators seem to be involved in the process of 
cuprizone-induced demyelination (Fig. 6). Some of this evi-
dence includes: 1) Production of NO by upregulating induc-
ible nitric oxide synthase (iNOS) and the neuronal isoform 
(nNOS), which strongly determine the demyelinating proc-
ess as demonstrated in eNOS-/- mice [30, 31]. 2) Inflamma-
tory cytokines produced by microglia and astrocytes that 
have a cytotoxic role and promote the overexpression of the 
endothelial nitric oxide synthase (eNOS) [16]. 3) Astrocyte 
production of interleukin-6 (IL-6) and interleukin-17 (IL-17) 
resulted in functional deficits associated with accelerated 
demyelination, reduced myelin synthesis and microglia acti-
vation [65, 99]. 4) Overexpression of CXCL10 produced by 
astrocytes that induces reactive microglia and, in turn, in-
creases the levels of TNFα [13]. 5) IFN-γ that is crucial in 
the demyelinating process as demonstrated in transgenic 
mice that express low level of IFN-γ under the transcrip-
tional control of MBP gene (MBP/IFN-γ mice) and display 
almost null evidence of injury in the white matter after CPZ 
administration [100-102]. 6) Interferon-beta (IFN-β) absence 
promotes remyelination by increasing the proliferation of 
oligodendroglial precursors cells [103]. 7) Activation of neu-
trophils that express the type 2 chemokine receptor 
(CXCR2) and trigger demyelination, as observed in CXCR2-
/- mice that are resistant to CPZ-induced demyelination 
[104]. Taken together, this evidence suggests that the im-
mune system is a key component in the cascade of events 
triggered by cuprizone administration. Therefore, this model 
may represent an plausible tool for studying the role of im-
mune system in the process of demyelination [30]. 
 
Fig. (6). Growth factors, cytokines, chemokines, and matrix metalloproteinases expressed in the medial corpus callosum during de-
myelination and remyelination in cuprizone treatment. The diagram depicts the expression levels of several molecules at different time 
points of the CPZ-induced demyelination. GDNF: Glial cell-derived neurotrophic factor; NRG1: neuroregulin -1; CCL: chemokine (C-C 
motif) ligand (2, 3 & 5); IL-1β: interleukin-1β; IGF: insulin like growth factor-1; LIF: Leukemia inhibitory factor; TGF-1β: transforming 
growth factor 1β; TNF-α: Tumor necrosis factor-α; TIMP1/2: tissue inhibitor of metalloproteinase 1 & 2; FGF-2: fibroblast growth factor 2; 
MMP: matrix metalloproteinase (3 &12); HGF: hepatocyte growth factor; OPN: osteopontin; CNTF: Ciliary neurotrophic factor; EGF: epi-
dermal growth factor; BDNF: brain-derived neurotrophic factor. 
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CONCLUSION 
 The CPZ model is a highly reproducible and easily im-
plemented animal model that produces very consistent de-
myelinating lesions. The white matter damage, oligodendro-
cyte apoptosis and microglial activation induced by CPZ 
mimics some of the aspects of demyelinating diseases. Thus, 
CPZ model has some characteristics that help study the in-
teractions between the immune system with the oligodendro-
cyte damage and myelin disruption, which can provide cru-
cial information to test potential therapies against demyeli-
nating diseases. Although it is generally accepted that CPZ 
model induces extended demyelination and important his-
tological changes, the complete cascade of biochemical 
events triggered by CPZ remains unclear. In addition, more 
research needs to be done to establish these mechanisms and 
clarify the pathways on how CPZ can reach the brain. 
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